ENLIVEN THERAPEUTICS, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2018 | — | $-26.3M | $7.4M |
| FY2019 | — | $-48.8M | $4.9M |
| FY2020 | — | $84.4M | $47.7M |
| FY2021 | — | $-42.9M | $48.3M |
| FY2022 | — | $-76.8M | $75.5M |
| FY2023 | — | $245.9M | $100.1M |
| FY2024 | — | $309.8M | $124.1M |
| FY2025 | — | $459.6M | $98.9M |